Compare Heron Therapeutics Inc (HRTX) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs LTC Properties Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while LTC Properties Inc trades at $43.29 (market cap $2.25B). The key difference: LTC Properties Inc is far larger — about 30.4× Heron Therapeutics Inc's market cap, and LTC Properties Inc pays a 5.45% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and LTC Properties Inc for 89 Days on average.
| HRTX | LTC | |
|---|---|---|
Market Cap | $74.04M | $2.25B |
Volume | 3,668,095 | 1,238,557 |
Sector | Health | Real Estate |
52-Week High | $1.49 | $43.50 |
52-Week Low | $0.27 | $33.98 |
Typical Hold Time | 35 Days | 89 Days |
Enterprise Value | $180.78M | $2.99B |
Dividend Yield | — | 5.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
LTC Properties trades at $41.81, down 1.48% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The REIT maintains strong profitability with 38.93% net margins and pays consistent monthly dividends of $0.19 per share. Recent acquisitions totaling $360 million accelerate the company's SHOP portfolio transformation, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with demographic tailwinds in senior housing but faces execution risks from aggressive expansion. The stock trades at reasonable valuations (P/E 14.93) with upside to analyst targets, though rising interest rates and integration challenges warrant caution for the growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
